At Drug Hearing, Senators Discuss Meanings of Price and Value - and Debate Health Reform image

Health Affairs Blog, June 20, 2017
Rachel E. Sachs (Academic Fellow Alumna)


Read the Full Article

From the article by Rachel E. Sachs, (Academic Fellow Alumna):

On Tuesday, June 13, the Senate Health, Education, Labor, & Pensions (HELP) Committee held the first of three planned hearings on high drug prices. This hearing, titled “How the Drug Delivery System Affects What Patients Pay,” was designed to elicit basic information about how drug prices, overall spending, and patient costs have changed over time, and about the drivers of these metrics. The hearing featured four non-industry witnesses, with the plan that industry representatives will be included in future hearings.

One of the most important points to come out of the hearing was that there is bipartisan concern about high drug prices. Even if there is as yet little agreement on what to do about it, Senators of both parties came out against the heavy burdens high drug prices have put on patients. 

Read the full article here

health care reform health law policy pharmaceuticals rachel sachs regulation